跳到正文
ISPE iSpeak 专家博客·· 2 天前AI 评分54

ISPE 博客第二部分探讨 AI 在动态控制策略、模型验证与检查准备中的应用边界

Expanding the Pharmaceutical Quality Framework, Part 2: Leveraging AI-Derived Insights Across CMC, Process Validation, and Quality Systems

AI 导读

ISPE iSpeak 博客第二部分梳理 AI 在动态控制策略、模型生命周期验证和检查准备中的用法与边界。文章提出 AI 模型生命周期需覆盖数据完整性与治理、模型架构与可解释性、验证与确认、前瞻性影子运行、漂移监测以及再训练与变更控制六项要素。文中说明 FDA 2023 年 AI 讨论文件和 EMA 2023 年反思文件应按系统、产品和辖区判断适用性,不应视为统一的强制性 AI 验证标准。

正文 · 原文
  1. CPP identification
  2. CQA–CPP relationship modeling
  3. Dynamic control strategy development
  4. AI model validation and lifecycle management
  5. Inspection readiness and regulatory compliance
  6. AI-supported deviation management and root cause analysis
  7. Bridging the six applications together
  8. Practical roadmap for industry

Section 1 and 2 are covered in part 1;
Sections 3, 4 and 5 are covered in part 2;
Sections 6, 7 and 8 are covered in part 3.

3. Dynamic Control Strategies Development

Rethinking the Pharmaceutical Control Strategy

International Council for Harmonisation (ICH) guideline Q8(R2) describes a design space as the multidimensional combination and interaction of input variables and process parameters demonstrated to provide assurance of quality1.

Traditional process control often uses predefined parameter ranges, established operating limits, and manual adjustments. These remain important components of pharmaceutical manufacturing.

However, fixed operating ranges may not fully capture the changing relationships between material attributes, process conditions, and quality outcomes.

AI can support more responsive control strategies by incorporating current process measurements, upstream material information, and predictions of future process behavior.

It is important to distinguish between an AI-recommended adjustment, an adjustment implemented through a validated control system, and a regulatory change to an approved manufacturing process. These are not interchangeable.

Model Predictive Control and AI-assisted optimization

Model predictive control (MPC) uses a process model to predict future behavior and evaluate possible control actions over a defined horizon.

An AI-enhanced MPC system could use process analytical technology (PAT) measurements and process history to recommend adjustments to feed rates, temperature, pH, agitation, or other process variables.

For example, if a bioreactor model predicts that an emerging metabolic shift may increase the risk of a product quality excursion, the controller could evaluate corrective actions before a critical quality attribute (CQA) moves outside its acceptable range.

Reinforcement learning (RL) may also be investigated in simulation environments or digital twins to identify promising control policies. However, deploying RL directly in a regulated manufacturing environment requires rigorous assessment of safety, stability, reproducibility, and the boundaries of permitted operation.

Feed-Forward Quality Management

AI can also connect upstream material attributes to downstream processing decisions.

Suppose a raw material’s molecular weight distribution or particle size differs from its historical average but remains within its approved specification. A validated predictive model may indicate that the difference could have an impact on granulation, drying, blending, or dissolution performance.

The manufacturing system could use this information to recommend an appropriate operating strategy before processing begins.

Any adjustment must remain consistent with established procedures, validated operating ranges, and applicable regulatory commitments.

Predictive Out-of-Trend Monitoring

Recurrent neural networks (RNNs), including Long Short-Term Memory (LSTM) networks and Gated Recurrent Units (GRUs), can analyze time-series sensor data to identify developing process deviations.

Where supported by prospective performance evidence, these models may provide earlier warnings than conventional threshold-based monitoring.

For example, a model may detect a combination of temperature, feed rate, and dissolved oxygen trends associated with a potential process excursion.

The value of such a warning depends on its sensitivity, false-alarm rate, lead time, and ability to support an effective intervention.

What Makes an AI-Supported Control Strategy Acceptable?

A defensible control strategy should establish:

  • The process variables and CQAs the system is intended to influence
  • The validated operating boundaries within which actions are permitted
  • The evidence supporting model accuracy and robustness
  • The conditions that trigger operator notification or intervention
  • The fallback strategy for sensor failure, model uncertainty, or system unavailability
  • The change control and documentation requirements for model updates

The objective is not simply to automate more decisions, it is to create a control strategy that maintains product quality while preserving accountability, traceability, and appropriate human oversight.

4. AI Models Validation and Lifecycle Management

Why AI Validation Requires a Lifecycle Approach

An AI model is not necessarily static after its initial qualification. Its performance can be affected by new raw material suppliers, equipment changes, sensor replacement, changes in operating conditions, or shifts in the relationship between process inputs and quality outcomes.

Consequently, the validation of AI used in pharmaceutical CMC and quality systems must address the complete model lifecycle.

Relevant considerations include applicable GxP requirements, electronic record controls, data integrity, risk-based computerized system validation, and the specific intended use of the model.

US Food and Drug Administration’s (US FDA) 2023 discussion paper on AI in drug development and manufacturing, the European Medicines Agency’s 2023 reflection paper, and the principles of good machine learning practice provide useful context for evaluating AI applications2, 3, 4. Their applicability depends on the system, product, jurisdiction, and intended use; they should not be interpreted as a single universally binding AI validation standard.

Six Elements of an AI Model Lifecycle

a. Data Integrity and Governance

Training, validation, and test datasets should be appropriately controlled, traceable, and representative of the intended use.

ALCOA+ principles, Attributable, Legible, Contemporaneous, Original, Accurate, and the associated completeness, consistency, endurance, and availability expectations, provide a useful framework for data integrity5.

Data lineage, inclusion and exclusion criteria, preprocessing operations, feature engineering, and dataset versions should be documented.

b. Model Architecture and Explainability

Model selection should reflect the risk of the intended application, the complexity of the process, the available evidence, and the consequences of an incorrect prediction.

Where decisions are consequential, explanation methods such as SHAP or Local Interpretable Model-agnostic Explanations (LIME) may help users understand model behavior.

Explainability alone does not demonstrate model correctness. It should be considered alongside performance testing, scientific plausibility, robustness, and intended-use validation.

c. Verification and Qualification

Model evaluation should include suitable training, validation, and independent testing procedures.

Depending on the application, testing may include cross-validation, temporal holdouts, site-specific evaluation, stress testing, sensitivity analysis, and assessment of performance under relevant edge cases.

The acceptance criteria should be predefined and linked to the intended use and associated quality risks.

d. Prospective Verification and Shadow Execution

Before a model is allowed to influence manufacturing decisions, shadow execution can help assess how it performs on live or newly generated data without controlling the process.

This approach provides an opportunity to compare model predictions with laboratory results, established process measurements, and decisions made by qualified personnel.

Prospective evidence is particularly important when historical datasets may not represent future manufacturing conditions.

e. Continuous Performance and Drift Monitoring

Two forms of drift deserve particular attention:

  • Data drift: A change in the distribution of model inputs, such as a shift in raw material attributes or sensor measurements
  • Concept drift: A change in the relationship between model inputs and the outcome being predicted

Statistical measures, including the Population Stability Index and Wasserstein distance, can help identify input distribution changes. Performance monitoring against reliable reference measurements can help determine whether predictive accuracy has deteriorated.

A detected shift does not automatically invalidate a model, but it should trigger an assessment based on predefined criteria.

f. Retraining and Change Control

Retraining should be governed by a documented process that defines when updates are permitted, how new data are selected, which tests must be repeated, and who approves deployment.

Predetermined change control plans (PCCPs) may be relevant in certain regulatory contexts, but their availability and scope depend on the applicable framework and regulatory commitments. A PCCP should not be assumed to authorize unrestricted changes to a pharmaceutical manufacturing model.

Practical Implication

AI model validation should be risk-based, intended-use-specific, and maintained throughout the model’s operational life.

The goal is to demonstrate that a model remains fit for its intended purpose, not merely that it performed well on its original training dataset.

5. Inspection Readiness and Regulatory Compliance

Making AI Decisions Traceable

Inspection readiness becomes more challenging when AI systems contribute to manufacturing decisions, quality investigations, or process control.

An organization must be able to explain what the system did, which information it used, what version of the model was involved, and how the resulting recommendation or action was reviewed and approved.

A technically sophisticated model that cannot be reconstructed or adequately explained may be difficult to defend during a regulatory inspection.

Establishing a Complete Audit Trail

A robust AI governance framework should support traceability across the complete decision lifecycle.

Model and Dataset Version Control

Records should link a prediction or action to the relevant model version, model parameters, training dataset version, preprocessing configuration, software environment, and applicable configuration settings.

For neural networks, this may include model weights and architecture versions. For other algorithms, the relevant artifacts will differ.

Prediction and Action Logging

Where required by the system’s risk assessment and applicable regulations, records should capture the relevant inputs, outputs, uncertainty estimates, timestamps, model version, system status, and human decisions.

For automated control, the audit trail should also record the action taken, the rationale or governing rule, any operator override, and the resulting process response.

Reproducibility and Record Retention

Records must be protected against unauthorized alteration and retained in accordance with applicable requirements. Immutable or write-once-read-many storage can be one technical safeguard, but it does not by itself establish compliance.

The overall solution must preserve record integrity, accessibility, reviewability, and appropriate access controls.

Human Oversight and Levels of Automation

AI applications can be organized conceptually according to their operational risk and degree of autonomy.

Level 1: Analytical Decision Support

AI identifies potential CPPs, unusual patterns, or likely root causes. Qualified personnel review the findings and determine whether further investigation or formal change control is required.

Level 2: Bounded Process Automation

A validated system adjusts process variables within established limits. Operators retain appropriate override capabilities, and the system includes defined exception handling and fallback behavior.

Level 3: Highly Automated Quality Decisions

AI contributes to consequential decisions, potentially including elements of real-time release testing. This use requires a particularly strong evidence base, including validated analytical methods, model performance evidence, suitable process control, and compliance with applicable regulatory expectations.

These levels are illustrative categories, not a universal regulatory classification scheme.

The level of assurance required should be determined by the model’s intended use, the severity of potential failure, the degree of automation, and the availability of independent safeguards.

Practical Implication

Inspection readiness should be designed into the AI lifecycle from the outset. Documentation, access controls, traceability, reproducibility, change management, and human accountability are essential elements of the implementation, not administrative tasks to complete after deployment.

Disclaimer

iSpeak blog posts provide an opportunity for the dissemination of ideas and opinions on topics impacting the pharmaceutical industry. Ideas and opinions expressed in iSpeak blog posts are those of the author(s) and publication thereof does not imply endorsement by ISPE.

来源:ISPE iSpeak 专家博客 · ispe.org

所属事件

查看事件全部
ISPE博客:AI辅助CPP识别与模型验证边界